<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of cancer anorexia/cachexia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of cancer anorexia/cachexia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of cancer anorexia/cachexia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles L Loprinzi, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Aminah Jatoi, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul J Hesketh, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The cancer-related anorexia/cachexia syndrome (CACS) is characterized by anorexia and a loss of body weight associated with reduced muscle mass and adipose tissue. In addition to a variable contribution from decreased energy intake, resting energy expenditure can be elevated in CACS in association with increases in both muscle protein breakdown and lipolysis, changes that appear to be due in part to an inflammatory response with the elaboration of cytokines, including tumor necrosis factor-alpha, interleukin (IL) 6, and IL-1 beta. Tumor-elaborated factors may play an important role. Unlike starvation, weight loss in cancer arises both from loss of muscle and fat. (See  <a class="medical medical_review" href="/z/d/html/2817.html" rel="external">"Pathogenesis, clinical features, and assessment of cancer cachexia"</a>.)</p><p>This topic review will cover treatment for patients with CACS. The clinical features and pathogenesis of CACS, diagnostic criteria for CACS, oral and parenteral nutritional support for patients with cancer, and a general discussion of assessment and management of anorexia/cachexia in palliative care patients with advanced life-threatening illness are provided elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2817.html" rel="external">"Pathogenesis, clinical features, and assessment of cancer cachexia"</a> and  <a class="medical medical_review" href="/z/d/html/2830.html" rel="external">"The role of parenteral and enteral/oral nutritional support in patients with cancer"</a> and  <a class="medical medical_review" href="/z/d/html/83234.html" rel="external">"Assessment and management of anorexia and cachexia in palliative care"</a>.)</p><p class="headingAnchor" id="H1567976308"><span class="h1">PREVALENCE AND CLINICAL SIGNIFICANCE</span><span class="headingEndMark"> — </span>The CACS is frequently seen in patients with advanced cancer. One study evaluated 644 consecutive, mostly ambulatory cancer patients; decreased appetite, decreased food intake, and weight loss in excess of 5 percent of premorbid weight were present in more than one-half [<a href="#rid1">1</a>]. Furthermore, 54 percent were underweight when compared with the calculated ideal body weight.</p><p>Weight loss in CACS is a marker for both progression of the syndrome and for prognosis [<a href="#rid2">2</a>]. In a multi-institutional, retrospective review of 3047 clinical protocol cancer patients from the Eastern Cooperative Oncology Group, weight loss of more than 5 percent of premorbid weight prior to the initiation of chemotherapy was predictive of early mortality. Weight loss was independent of disease stage, tumor histology, and patient performance status in its predictive value [<a href="#rid2">2</a>]. There was also a trend towards lower response rates with the use of chemotherapy among weight-losing patients. This trend reached statistical significance only among patients with breast cancer.</p><p class="headingAnchor" id="H1567976427"><span class="h1">OVERVIEW OF ASSESSMENT AND MANAGEMENT</span><span class="headingEndMark"> — </span>All cancer patients should be assessed for nutritional status and weight loss. The clinical assessment for patients with anorexia or cachexia includes a careful history that is focused on nutritional issues including risk factors that compromise the ability to obtain or take in nutrition, and a physical examination focusing on loss of subcutaneous fat, muscle wasting (temporal region, deltoids, and quadriceps with loss of bulk and tone by palpation), edema (sacral or ankle), or ascites. The most commonly used objective measures of nutritional status are serial measurement of body weight and assessment of dietary intake, while subjective information on nutritional status can be provided by malnutritional assessment tools. Laboratory measures of nutritional status (eg, albumin, transferrin) are rarely needed for assessment of nutritional status, although some screening tools (eg, the Nutrition Risk Index) do include a measurement of serum albumin. These issues are all addressed in more detail elsewhere. Of note, substantial data do support that computed tomography-estimated muscle mass is an effective means of determining whether a patient has sarcopenia. (See  <a class="medical medical_review" href="/z/d/html/83234.html" rel="external">"Assessment and management of anorexia and cachexia in palliative care", section on 'Clinical assessment'</a>.)</p><p>Our approach to management of CACS follows published guidance from the American Society of Clinical Oncology (ASCO) [<a href="#rid3">3,4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Communication regarding cachexia management and issues around feeding, particularly in the setting of advanced cancer or end of life care, should involve caregivers as well as patients. (See <a class="local">'Psychosocial impact and counseling'</a> below.)</p><p></p><p class="bulletIndent1">Optimizing management of major contributors to anorexia, such as chronic nausea, constipation, taste alterations, dyspnea, and depression (nutrition impact symptoms) may improve appetite. (See <a class="local">'Treating nutrition impact symptoms'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Referral of patients with CACS to a registered dietician can provide important support to patients and their caregivers, although referral is not mandatory for all patients. The goals include practical and safe advice for feeding; education regarding high-protein, high-calorie, nutrient-dense food; and advice against fad diets and other unproven or extreme diets. (See <a class="local">'Dietary counseling'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most patients with advanced cancer and CACS, we suggest not routinely using enteral tube feeding or <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> to manage cachexia. A short-term trial of parenteral nutrition may be offered to a very select group of patients, such as those who have a reversible bowel obstruction, short-bowel syndrome, or other issues contributing to malabsorption, but are otherwise reasonably fit. Discontinuation of previously initiated parenteral or enteral nutrition near the end of life is appropriate. (See <a class="local">'Parenteral or nonvolitional enteral nutrition'</a> below and  <a class="medical medical_review" href="/z/d/html/2830.html" rel="external">"The role of parenteral and enteral/oral nutritional support in patients with cancer", section on 'Indications and benefits of nutritional support in cancer patients'</a> and  <a class="medical medical_review" href="/z/d/html/83234.html" rel="external">"Assessment and management of anorexia and cachexia in palliative care", section on 'Indications for artificial nutritional support'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The decision to use pharmacologic agents for appetite stimulation is highly dependent on the values and preferences of individual patients and other considerations such as degree of anorexia or weight loss, comorbidities, risk of adverse effects, life expectancy, and goals of care. The primary benefits associated with these drugs are increased appetite and modest weight gain, not improved survival. (See <a class="local">'Potentially beneficial agents'</a> below.)</p><p></p><p class="bulletIndent1">When it is decided that a pharmacologic agent should be used, we use relatively low doses of <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> (2.5 to 5 mg/day). Data supporting the use of this drug come from three clinical trials [<a href="#rid5">5-7</a>]. Consistent with updated ASCO guidelines [<a href="#rid4">4</a>], another option is to use a <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> analog (<a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a> or <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a>) or <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, but potential benefits must be balanced with risks (edema, thromboembolic events, increased mortality). (See <a class="local">'Progesterone analogs'</a> below and <a class="local">'Glucocorticoids'</a> below.)</p><p></p><p class="bulletIndent1">We recommend against the use of hydrazine sulfate. We suggest not using inhaled cannabinoids, cannabis, inhibitors of tumor necrosis factor, insulin, or melatonin. (See <a class="local">'Not recommended'</a> below.)</p><p></p><p class="bulletIndent1">Evidence is inconclusive regarding the benefits of many other treatments, including androgens and selective androgen receptor modulators; anamorelin; <a class="drug drug_general" data-topicid="9311" href="/z/d/drug information/9311.html" rel="external">cyproheptadine</a>; long-chain omega-3 fatty acids; vitamins, minerals, and other dietary supplements; nonsteroidal anti-inflammatory drugs; <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>; <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a>; and combination approaches, and thus, there is insufficient evidence to recommend either for or against the use of these agents. (See <a class="local">'Insufficient evidence to recommend for or against'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Outside of the context of a clinical trial, no recommendation can be made for other interventions such as exercise; although, exercise, as tolerated, is generally a good clinical recommendation for most patients. (See <a class="local">'Exercise'</a> below.)</p><p></p><p class="headingAnchor" id="H4028345864"><span class="h1">GENERAL ASPECTS</span></p><p class="headingAnchor" id="H1692958382"><span class="h2">Psychosocial impact and counseling</span><span class="headingEndMark"> — </span>Loss of appetite and alterations in appearance as a result of cachexia are distressing to patients and especially to their caregivers and family [<a href="#rid8">8</a>]. Caregivers may misinterpret lack of eating as a failure of the caregiver to provide adequate care, and this may be compounded by familial and/or cultural beliefs that equate feeding and sharing food with the demonstration of love and hope [<a href="#rid9">9,10</a>].</p><p></p><p>The social benefits of being at the dining table with other family members should be encouraged. The pleasure of tasting food should be emphasized over total caloric intake. In general, patients with anorexia/cachexia syndrome who are able to eat should be recommended to have small, frequent meals that are dense in calories (eg, eggs, liquid nutritional supplements). Other strategies to enhance caloric intake include eating meals that require little preparation (eg, microwaveable) and resting before meals.</p><p>Issues around eating and feeding can become more difficult near the end of life; the following discussion points should be emphasized with both patients and their caregivers [<a href="#rid3">3,11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Loss of appetite is common in patients with advanced cancer and may be the result of the cancer process itself.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Trying to force a patient to eat is usually counterproductive, potentially leading to increased aspiration, nausea and/or vomiting. Furthermore, when marked appetite loss is present, such efforts can lead to decreased social interactions and increased patient distress and possible avoidance regarding interactions with family and caregivers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most patients with advanced cancer and cachexia, providing extra calories by feeding tubes and/or the intravenous route does not improve outcomes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For caregivers, it might be best to listen to and support the patient in a variety of other ways (eg, giving the patient a massage or applying lip moisturizer) instead of trying to talk them into eating more.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Referral to a registered dietician may provide patients and their caregivers an opportunity to discuss concerns and challenges related to nutrition, appetite, and meal planning. However, referral is not mandatory for all patients.</p><p></p><p class="headingAnchor" id="H18749185"><span class="h2">Treating nutrition impact symptoms</span><span class="headingEndMark"> — </span>Symptoms such as depression, dysgeusia, pain, excessive drowsiness, nausea, and constipation may contribute to poor oral intake. These nutrition impact symptoms are frequent among patients with CACS, and they are associated with adverse outcomes such as weight loss and shorter survival [<a href="#rid12">12,13</a>]. Retrospective studies suggest clinical benefit from successful treatment of secondary nutrition impact symptoms [<a href="#rid12">12,13</a>]. (See  <a class="medical medical_review" href="/z/d/html/83234.html" rel="external">"Assessment and management of anorexia and cachexia in palliative care", section on 'Dietary and lifestyle modifications'</a> and  <a class="medical medical_review" href="/z/d/html/83234.html" rel="external">"Assessment and management of anorexia and cachexia in palliative care", section on 'Secondary nutrition impact symptoms'</a>.)</p><p class="headingAnchor" id="H1987115135"><span class="h1">DIETARY COUNSELING</span><span class="headingEndMark"> — </span>Referral of patients with CACS to a registered dietician can provide important support to patients and their caregivers. The evidence to support benefit from dietary counseling and oral nutritional supplementation or both in terms of weight gain and improved appetite is limited and inconclusive, in part because of a lack of a clear definition of these interventions [<a href="#rid14">14-17</a>]. However, a dietician can help individual patients meet estimated protein and caloric needs as much as possible, and discourage the use of potentially harmful dietary supplement use, and fad, unproven, or extreme diets [<a href="#rid3">3</a>]. One-half or more of cancer patients have reported using dietary supplements during treatment and either pursue or are interested in extreme or unproven forms of dietary restriction [<a href="#rid18">18,19</a>].</p><p class="headingAnchor" id="H4070129672"><span class="h1">PARENTERAL OR NONVOLITIONAL ENTERAL NUTRITION</span><span class="headingEndMark"> — </span>For most patients with advanced cancer and CACS, we suggest not routinely using enteral tube feeding or <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> to manage cachexia. However, there are specific situations in which a patient has a nonfunctioning alimentary tract but does not have extensive organ involvement by a cancer that portends a very poor prognosis [<a href="#rid3">3</a>]. One example is a patient with a relatively indolent malignancy causing a multifocal bowel obstruction. However, even in such situations, the risks, benefits, and cost of total parenteral nutrition (TPN) should be discussed with the patient and caregivers. If such a trial is initiated, benefit should be evaluated after a fixed time period with a specific goal. If no significant benefit has occurred, and when death appears imminent, TPN should be stopped. (See  <a class="medical medical_review" href="/z/d/html/14244.html" rel="external">"Stopping nutrition and hydration at the end of life"</a>.)</p><p>The indications, benefits, and harms of parenteral and enteral nutritional support in advanced cancer are provided in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2830.html" rel="external">"The role of parenteral and enteral/oral nutritional support in patients with cancer", section on 'Indications and benefits of nutritional support in cancer patients'</a>.)</p><p class="headingAnchor" id="H148793978"><span class="h1">PHARMACOLOGIC TREATMENTS</span></p><p class="headingAnchor" id="H591364273"><span class="h2">Potentially beneficial agents</span><span class="headingEndMark"> — </span>There are no US Food and Drug Administration (FDA)-approved medications for treatment of CACS. The decision to use pharmacologic agents for appetite stimulation in cancer patients with cachexia is highly dependent on the values and preferences of the patents and other considerations such as degree of anorexia or weight loss, comorbidities, risk of adverse effects, life expectancy, and goals of care. The primary benefits associated with these drugs are increased appetite and modest weight gain, not improved survival.</p><p>If the decision is made to treat, three available, well-studied options are <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> analogs, and glucocorticoids.</p><p class="headingAnchor" id="H3008313728"><span class="h3">Olanzapine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">Olanzapine</a> (2.5 to 5 mg daily) is the preferred option for treating patients with cancer-associated anorexia/cachexia [<a href="#rid4">4</a>]. Supporting evidence comes from several randomized trials:</p><p class="bulletIndent1"><span class="glyph">●</span>In a double-blind randomized trial, 124 patients starting chemotherapy for lung, pancreaticobiliary, or stomach cancers were randomly assigned to <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> 2.5 mg daily or placebo [<a href="#rid6">6</a>]. Of note, patients in both arms received 5 mg/day of olanzapine for four days with each dose of chemotherapy. At least 5 percent weight gain occurred in 60 percent of patients in the olanzapine arm versus 9 percent of patients in the placebo arm (p &lt;0.001). Substantial appetite improvement was seen in 43 percent of the active therapy arm versus 30 percent of patients receiving a placebo (p &lt;0.001). Grade 3 chemotherapy toxicity was less common with olanzapine (12 percent versus 37 percent, p = 0.002). There was no apparent olanzapine-associated toxicity, with one patient noting potential drug toxicity with olanzapine versus two with placebo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional information came from a report of a randomized placebo-controlled trial of <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> in 30 patients with nausea and vomiting associated with advanced cancer who were not receiving chemotherapy or radiation therapy [<a href="#rid7">7</a>]. Appetite scores were unchanged in the placebo group at one week; however, scores improved significantly among those receiving olanzapine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Earlier evidence to support <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> came from a study that involved 80 patients with advanced gastrointestinal or lung cancer who were randomly assigned to <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a> alone at a dose of 800 mg/day or the same dose of megestrol plus olanzapine 5 mg/day for eight weeks [<a href="#rid5">5</a>]. The MD Anderson Symptom Inventory was used to objectively assess appetite. Patients receiving combined therapy had a significantly higher rate of improved appetite (64 versus 5 percent). In this trial, it is worth noting that the appetite stimulation with megestrol acetate was much less than has been noted in other trials. This may be because the patients had advanced cancer and were in a situation in which chemotherapy was not being administered.</p><p></p><p>Additional support for the potential utility of <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> for treatment of cancer cachexia is provided by data demonstrating considerable undesired weight gain among patients receiving olanzapine for psychiatric disorders. While most of the data that support the use of olanzapine for treating cancer-associated anorexia/cachexia come from patients with lung and abdominal cancers, it is reasonable to extrapolate these findings to patients with other types of cancers. One of the manuscripts supporting that olanzapine improved cancer-associated anorexia [<a href="#rid7">7</a>] included patients with breast, gynecologic, prostate, and genitourinary cancers. There are no substantial data that support a difference in the efficacy of olanzapine in any particular type of advanced cancer histology or in patients who are, or are not, receiving concomitant cytotoxic therapy.</p><p class="headingAnchor" id="H4"><span class="h3">Progesterone analogs</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">Megestrol acetate</a> improves appetite and body weight in patients with cancer cachexia, but the type of weight gain is primarily adipose tissue rather than skeletal muscle [<a href="#rid20">20</a>]. Toxicities include thromboembolic events, edema, and adrenal suppression. Similar findings have been observed with <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (MPA) [<a href="#rid21">21</a>].</p><p>A number of prospective, controlled randomized trials and several systematic reviews and meta-analyses have confirmed the modest efficacy of <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a> and MPA for palliation of CACS [<a href="#rid22">22-29</a>]. The effectiveness of megestrol acetate and its potential superiority to other classes of agents (at least in terms of toxicity) are illustrated by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>The advantages of <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> analogs over glucocorticoids and anabolic agents were demonstrated in a trial in which 475 patients with CACS were randomly assigned to treatment with <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a> (800 mg/day), <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (4 mg/day), or fluoxymesterone (20 mg/day) [<a href="#rid24">24</a>]. The megestrol acetate and dexamethasone had similar efficacy in terms of appetite stimulation and weight gain, and both were superior to fluoxymesterone (which is no longer available). However, toxicity was more common with dexamethasone (myopathy, cushingoid body habitus, and peptic acid disease), which led some patients to discontinue treatment. There was no difference between the treatment groups in survival or quality of life.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2013 Cochrane review of megestrol for anorexia/cachexia syndrome concluded that when compared with placebo, megestrol significantly improves appetite, weight, and quality of life, but that there is a lack of benefit when megestrol was compared with other drugs [<a href="#rid22">22</a>]. However, edema, thromboembolic events, and deaths were more frequent in the patients treated with <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a>. The authors concluded that megestrol was associated with increased mortality (relative risk 1.42, 95% CI 1.04-1.94), with greater risk at doses of ≥800 mg/day. A subsequent update concluded that such detrimental effects on survival are nonexistent [<a href="#rid30">30</a>].</p><p></p><p class="headingAnchor" id="H5"><span class="h4">Dose of megestrol acetate</span><span class="headingEndMark"> — </span>Some studies have addressed the optimal dosing of <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a> in patients with cancer [<a href="#rid31">31-34</a>]. In a dose-response trial, there was a positive relationship between appetite stimulation and increasing megestrol acetate doses ranging from 160 to 800 mg/day [<a href="#rid31">31</a>]. A higher dose, 1280 mg/day, was not more effective. The above-mentioned Cochrane review concluded that there was insufficient information to define the optimal dose of megestrol, but that higher doses (&gt;160 mg) were more related to weight gain than were lower doses [<a href="#rid22">22</a>]. On the other hand, mortality was more frequent in patients receiving doses ≥800 mg daily.</p><p>Most published studies tested <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a> tablets rather than the oral suspension. However, the liquid form is associated with good compliance, lower expense, and possibly better bioavailability. Our practice is to begin with liquid megestrol acetate at a dose of 400 mg/day in patients who really want appetite stimulation with megestrol acetate (as opposed to <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>), despite the risks noted above. While a dose-response trial illustrated that 800 mg per day stimulated appetite a little more than did 480 mg per day, this was with a tablet formulation that is not as bioavailable as is the liquid formulation. Also, cost factors do come into play [<a href="#rid31">31</a>]. A high-potency liquid formulation is available, which contains 625 mg in 5 mL, but may be considerably more expensive.</p><p class="headingAnchor" id="H6"><span class="h4">Side effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">Megestrol acetate</a> may increase the risk of edema and certainly increases thromboembolic problems [<a href="#rid22">22</a>], particularly in patients receiving concomitant chemotherapy [<a href="#rid35">35</a>]. Megestrol may cause symptomatic suppression of the hypothalamic pituitary adrenal axis [<a href="#rid36">36-38</a>]. In the presence of serious infection, surgery, or trauma, this complication may be life threatening if not anticipated and treated. In male patients with cancer, treatment with megestrol may also suppress the gonadal axis, resulting in symptomatic androgen deficiency [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/173.html" rel="external">"Causes of secondary and tertiary adrenal insufficiency in adults"</a>.)</p><p class="headingAnchor" id="H7"><span class="h4">Use in prophylaxis</span><span class="headingEndMark"> — </span>The efficacy of these agents in the treatment of CACS led investigators to study their role for prophylaxis of this problem. The benefit of prophylactic <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> analogs has not been seen despite several prospective randomized clinical trials, as is illustrated by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>In one trial, 243 patients with newly diagnosed, extensive-stage small cell lung cancer were randomly assigned to <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a> (800 mg/day) or placebo [<a href="#rid35">35</a>]. Although megestrol reduced nausea somewhat, there was no improvement in tumor response rate, survival, or quality of life. An increased incidence of thromboembolic events was observed in patients treated with megestrol acetate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second trial randomly assigned 134 patients with advanced, incurable, nonhormone-sensitive cancer to MPA (500 mg twice daily) or placebo [<a href="#rid39">39</a>]. At 12 weeks, MPA was associated with improved appetite and a mean weight gain of 0.6±4.4 kg compared with a mean weight loss of 1.4±4.6 kg in the placebo-treated group (p = 0.04 for the between group difference). However, there was no improvement in global quality of life.</p><p></p><p class="headingAnchor" id="H3246363664"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>Glucocorticoids improve appetite to a similar degree to that seen with <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> analogs. However, given the toxicities and decline in efficacy associated with long-term use, their role as an appetite stimulant often is limited to those with an estimated life expectancy of weeks to a couple of months.</p><p>The mechanism of action of corticosteroids in CACS has not been established. Euphorigenic and anti-inflammatory effects, and perhaps stimulation of orexigenic hormones within the hypothalamus, may be responsible for an increase in appetite.</p><p>At one time, glucocorticoids were first-line therapy for appetite stimulation in CACS. In the first placebo-controlled trial in CACS, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> alleviated cancer anorexia on a short-term basis [<a href="#rid40">40</a>]. This finding has subsequently been replicated by other studies, and both <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> and <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> have also been shown to be effective [<a href="#rid41">41,42</a>]. A year 2005 systematic review of six placebo-controlled trials reported improvement in appetite in most of the trials, but only two reported weight findings, with no significant improvement in the glucocorticoid arms [<a href="#rid25">25</a>]. The authors concluded that the optimal dose and duration of glucocorticoid use were unknown.</p><p>A reasonable dose of <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> in this setting is 4 mg/day, although lower doses may also be effective.</p><p>Many patients treated with glucocorticoids experience an increase in appetite and sense of wellbeing but not weight gain, compared with placebo [<a href="#rid40">40-42</a>]. However, the duration of appetite stimulation is often short-lived. Furthermore, prolonged steroid therapy produces myopathy and a wide variety of other side effects. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H2551262066"><span class="h2">Insufficient evidence to recommend for or against</span><span class="headingEndMark"> — </span>The evidence is inconclusive regarding the benefits of many other treatments for cancer cachexia, including androgens and selective androgen receptor modulators; anamorelin; <a class="drug drug_general" data-topicid="9311" href="/z/d/drug information/9311.html" rel="external">cyproheptadine</a>; long-chain omega-3 fatty acids; vitamins, minerals, and other dietary supplements; nonsteroidal anti-inflammatory drugs (NSAIDs); <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>; <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a>; and combination therapies. None of these approaches can be recommended at present.</p><p class="headingAnchor" id="H2925826257"><span class="h3">Androgens and selective androgen receptor modulators</span><span class="headingEndMark"> — </span>Anabolic steroids have been hypothesized to have a selective effect that induces an increase in lean body mass, even while body fat decreases and there is a decrease in overall weight. Two systematic reviews of cachexia management [<a href="#rid25">25,29</a>] have included three randomized trials of androgens or androgen receptor modulators:</p><p class="bulletIndent1"><span class="glyph">●</span>In a three-arm trial described above in which 475 patients with CACS were randomly assigned to treatment with <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a> (800 mg/day), <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (4 mg/day), or fluoxymesterone (20 mg/day), megestrol was better than fluoxymesterone for improving appetite [<a href="#rid24">24</a>]. (See <a class="local">'Progesterone analogs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an early trial of 37 patients with non-small cell lung cancer (NSCLC) receiving chemotherapy, patients who were randomly assigned to four weeks of nandrolone were less likely to lose weight than were those in the control group (12 versus 25 percent) but the difference was not statistically significant [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of antiandrogen therapy is also supported by a placebo-controlled trial evaluating the benefit of the selective androgen receptor modulator enobosarm (GTx-024) in 159 patients with weight loss due to cancer [<a href="#rid44">44</a>]. Compared with baseline, patients assigned to either of two doses of enobosarm had significant increases in lean body mass for up to 113 days (median 1.2 and 1 kg with 1 and 3 mg daily, respectively), while changes in lean body mass with placebo (median 0.2 kg) were not statistically significant.</p><p></p><p class="bulletIndent1">Further phase III studies of enobosarm have been completed [<a href="#rid45">45</a>], but published results are not available. Enobosarm is not commercially available in any country.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Modest benefit was also suggested in a small double-blind placebo-controlled trial of weekly injections of <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> enanthate in 28 patients with cancer-associated loss of muscle mass [<a href="#rid46">46</a>]. Those randomized to testosterone increased lean body mass by 3 percent, compared with a loss of 3 percent in the control group.</p><p></p><p class="headingAnchor" id="H3770877014"><span class="h3">Growth hormone and ghrelin analogs (anamorelin)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9456" href="/z/d/drug information/9456.html" rel="external">Recombinant human growth hormone</a> in conjunction with protein restriction increased skeletal muscle mass at the expense of the tumor when used in animals [<a href="#rid47">47</a>]. However, the use of recombinant growth hormone in critically ill adults has been associated with high mortality rates, perhaps because of a diversion of amino acids and energy to skeletal muscle and away from the acute phase response, thus blunting host defenses [<a href="#rid48">48,49</a>].</p><p>An alternative approach has been the use of ghrelin, which is a ligand for growth hormone secretagogue receptor and can induce release of growth hormone. Preliminary small, randomized studies have shown that multiple doses of parenteral ghrelin therapy can be safely administered to patients with advanced cancer [<a href="#rid50">50-52</a>]. However, only one of these trials was placebo controlled, and a Cochrane review of all three trials (totaling only 59 cancer patients) concluded that there is insufficient evidence to support or refute any benefit of ghrelin in people with cancer cachexia [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/z/d/html/5380.html" rel="external">"Ghrelin"</a>.)</p><p>On the other hand, studies of anamorelin, an oral ghrelin mimetic, in palliative care populations have been promising [<a href="#rid54">54-61</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>ROMANA 1 (n = 484) and ROMANA 2 (n = 495) were identically designed phase III studies that randomly assigned patients with inoperable stage III or IV NSCLC and cachexia in a 2:1 ratio to receive either anamorelin (100 mg daily) or placebo for 12 weeks in conjunction with chemotherapy [<a href="#rid56">56</a>]. Cachexia was defined as a ≥5 percent weight loss within the past six months or body mass index (BMI) &lt;20 kg/m<sup>2</sup>. In both studies, patients randomly assigned to placebo continued to lose lean body mass while those receiving anamorelin gained (at 12 weeks, +0.99 versus -0.47 kg with placebo in ROMANA 1; +0.65 versus -0.98 kg with placebo in ROMANA 2). Patients assigned to anamorelin also had a significant increase in body weight (2.2 versus 0.14 kg in ROMANA 1, and 0.95 versus -0.57 kg in ROMANA 2) and significant improvement in anorexia/cachexia symptoms. There were no significant differences in fist-grip strengths between the two study arms, and survival curves were overlapping. The most common adverse events were nausea and hyperglycemia.</p><p></p><p class="bulletIndent1">In a later extension study of 513 patients who were enrolled in both trials and who continued beyond 12 weeks (ROMANA 3), the improvements in weight and anorexia/cachexia symptoms were maintained over 12 to 24 weeks with no new signals for treatment-emergent adverse effects [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two meta-analysis reported improvements in body weight, lean body mass, and patient-reported quality of life with anamorelin [<a href="#rid59">59,63</a>]. In both, anamorelin did not improve overall survival or hand grip strength, and there were no significant differences between groups for frequency or severity of any adverse events.</p><p></p><p>Anamorelin has not received approval for use in treating cancer cachexia in the United States or Europe, but it has been approved (December 2020) for use in Japan, largely based upon weight gain observed in phase II trials.</p><p class="headingAnchor" id="H1559366140"><span class="h3">Cyproheptadine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9311" href="/z/d/drug information/9311.html" rel="external">Cyproheptadine</a> is a histamine and serotonin antagonist that has been observed to cause weight gain in observational studies of patients with advanced cancer. In a large, placebo-controlled trial that included 295 patients with the CACS, cyproheptadine (8 mg three times daily) had a mild stimulatory effect on appetite but failed to lead to weight gain [<a href="#rid64">64</a>].</p><p></p><p><a class="drug drug_general" data-topicid="9311" href="/z/d/drug information/9311.html" rel="external">Cyproheptadine</a> may be effective in patients with carcinoid syndrome who have anorexia/cachexia. In these patients, cyproheptadine presumably acts by directly counteracting increased serotonin activity [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/z/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors"</a>.)</p><p class="headingAnchor" id="H423222704"><span class="h3">Omega-3 fatty acids</span><span class="headingEndMark"> — </span>Long-chain omega-3 fatty acids are found in marine products, such as fish oil. In vitro studies have shown that these compounds can attenuate the stimulation of adenylate cyclase activity and lipolysis produced by tumor-derived lipid-mobilizing factor [<a href="#rid66">66</a>]. They may also suppress interleukin 6 production in patients with pancreatic cancer cachexia [<a href="#rid67">67</a>].</p><p>The effectiveness of omega-3 fatty acids has been assessed in a number of randomized trials, without consistent evidence of a beneficial effect [<a href="#rid68">68-76</a>]. A 2007 Cochrane database meta-analysis concluded that there were insufficient data to establish that supplementation with omega-3 fatty acids was better than placebo [<a href="#rid77">77</a>]; a similar conclusion was reached in a later 2012 systematic review [<a href="#rid78">78</a>]. On the other hand, a separate analysis that was limited to patients with pancreatic cancer suggested that consumption of omega-3 fatty acids may improve weight, lean body mass, and survival [<a href="#rid79">79</a>].</p><p>It is, however, reasonable to use these fats as a source of calories for patients with CACS. Natural sources of omega-3 fatty acids, such as salmon, are nutrient-dense foods and can be included in the diet as tolerated [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H2877425412"><span class="h3">Vitamins, minerals, and other dietary supplements</span><span class="headingEndMark"> — </span>Information from pilot studies suggested that specific amino acid nutritional formulations with branched chain amino acids, <a class="drug drug_general" data-topicid="8883" href="/z/d/drug information/8883.html" rel="external">arginine</a>, and <a class="drug drug_general" data-topicid="8747" href="/z/d/drug information/8747.html" rel="external">glutamine</a> might have had some efficacy in alleviating CACS [<a href="#rid80">80</a>]. However, placebo-controlled clinical trials have yet to be performed. At least one prospective, multicenter, placebo-controlled, randomized, double-blind trial of <a class="drug drug_general" data-topicid="10109" href="/z/d/drug information/10109.html" rel="external">carnitine supplements</a> (4 g daily) in 72 patients with advanced pancreatic cancer and weight loss reported an increase in BMI, quality of life, and a trend toward improved survival with carnitine supplements [<a href="#rid81">81</a>]. (See  <a class="medical medical_review" href="/z/d/html/2830.html" rel="external">"The role of parenteral and enteral/oral nutritional support in patients with cancer", section on 'The perioperative setting'</a>.)</p><p>Similarly, benefit from creatine could not be shown in a placebo-controlled randomized trial in 263 patients with CACS and advanced cancer [<a href="#rid82">82</a>].</p><p>A year 2017 systematic review evaluated vitamins, minerals, and other dietary supplements including magnesium, <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> in combination with omega-3 fatty acids, vitamin D, <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">vitamin C</a>, beta-hydroxy-beta-methylbutyrate, <a class="drug drug_general" data-topicid="8883" href="/z/d/drug information/8883.html" rel="external">arginine</a>, <a class="drug drug_general" data-topicid="8747" href="/z/d/drug information/8747.html" rel="external">glutamine</a>, and L-carnitine [<a href="#rid83">83</a>]. Although some studies reported improved lean body mass or BMI, the authors concluded that the evidence was insufficient to concluding that there was benefit to any of these approaches.</p><p class="headingAnchor" id="H86979544"><span class="h3">NSAIDs</span><span class="headingEndMark"> — </span>Two meta-analyses addressing the benefit of nonsteroidal anti-inflammatory drugs (NSAIDs) for treatment of cancer cachexia both concluded that NSAIDs improved body weight or quality of life in some studies, but the evidence was insufficient that there is clear evidence of benefit [<a href="#rid39">39,84</a>].</p><p>There are conflicting data as to whether NSAIDs enhance outcomes with megestrol in this setting, with one trial demonstrating no benefit from the addition of <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">celecoxib</a> to megestrol in 90 patients with a gastrointestinal cancer and weight loss [<a href="#rid85">85</a>], and a second trial suggesting that combined <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">ibuprofen</a> plus <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a> was better than megestrol plus placebo at maintaining weight [<a href="#rid86">86</a>]. (See <a class="local">'Combination therapy'</a> below.)</p><p class="headingAnchor" id="H3102751307"><span class="h3">Thalidomide</span><span class="headingEndMark"> — </span>The use of <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, a potent inhibitor of tumor necrosis factor (TNF)-alpha production, has been associated with weight gain in patients with tuberculosis or HIV infection. (See  <a class="medical medical_review" href="/z/d/html/83234.html" rel="external">"Assessment and management of anorexia and cachexia in palliative care", section on 'Other agents'</a>.)</p><p>There is insufficient evidence to refute or support the use of <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> for cancer cachexia:</p><p class="bulletIndent1"><span class="glyph">●</span>A 2012 Cochrane analysis could not perform a meta-analysis due to the small number and high heterogeneity of the studies. However, the narrative review concluded that there is insufficient evidence to support or refute the use of <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> for the management of cachexia in patients with advanced cancer [<a href="#rid87">87</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A year 2018 systematic review of pharmacologic agents for cancer cachexia included two randomized trials of <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> [<a href="#rid29">29</a>]. One small, placebo-controlled trial of 50 patients with advanced pancreatic cancer suggested modest benefits in preventing weight loss using thalidomide 200 mg/day [<a href="#rid88">88</a>]. However, other endpoints such as survival and quality of life showed no differences between groups. A year 2012 placebo-controlled trial was unable to draw clear conclusions [<a href="#rid89">89</a>].</p><p></p><p class="headingAnchor" id="H1718632877"><span class="h3">Mirtazapine</span><span class="headingEndMark"> — </span>At standard doses, the tetracyclic antidepressant <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a> induces weight gain and increases food intake. (See  <a class="medical medical_review" href="/z/d/html/1713.html" rel="external">"Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"</a>.)</p><p>Benefit in CACS was suggested in a phase II trial in which 17 nondepressed patients with CACS received an eight-week course of <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a> (15 to 30 mg by mouth daily) [<a href="#rid90">90</a>]. Four of 17 patients gained 1 kg or more, and 24 percent reported improved appetite. However, a more recent trial was not able to support any benefit for this drug [<a href="#rid91">91</a>].</p><p class="headingAnchor" id="H2140062620"><span class="h3">Combination therapy</span><span class="headingEndMark"> — </span>The role of combined therapy for treatment of CACS is unclear. Further studies are needed before it can be concluded that any combination of agents is safe and more effective than single-agent therapy.</p><p>Combinations that have been tested in controlled trials include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>As noted above, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> plus <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a> was better than megestrol acetate alone but was not compared with olanzapine alone [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">Ibuprofen</a> plus <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a> was reported to be better than megestrol plus placebo at maintaining weight [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another trial, <a class="drug drug_general" data-topicid="10109" href="/z/d/drug information/10109.html" rel="external">carnitine supplements</a> (4 g/day) and <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">celecoxib</a> (300 mg/day) with or without <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a> were studied and found to result in an identical response for the treatment of cancer cachexia [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Combinations of up to four different interventions have been studied preliminarily:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One trial included <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a> plus <a class="drug drug_general" data-topicid="10109" href="/z/d/drug information/10109.html" rel="external">carnitine supplements</a>, <a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">celecoxib</a>, and antioxidants compared with megestrol acetate alone in gynecological malignancies, and the combination arm was associated with improvement in lean body mass, resting energy expenditure, and global quality of life [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A randomized Italian trial attempted to address the role of combination therapy in patients with advanced stage cancer and CACS. In this five-arm study, 332 patients were randomly assigned to a four-month course of a <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a> analog (MPA or <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a>), an eicosapentaenoic acid-enriched nutritional supplement, <a class="drug drug_general" data-topicid="10109" href="/z/d/drug information/10109.html" rel="external">carnitine supplements</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, or a combination of all four interventions [<a href="#rid94">94</a>]. The combination arm appeared to have provided improved clinical outcomes, thereby suggesting that combination therapy merits further investigation.</p><p></p><p class="headingAnchor" id="H1613939189"><span class="h2">Not recommended</span></p><p class="headingAnchor" id="H8"><span class="h3">Cannabis and cannabinoids</span><span class="headingEndMark"> — </span>Unless the patient is participating in a clinical trial, we recommend against the use of synthetic cannabinoids, either as a single agent or in combination with megestrol, for treatment of CACS. We also suggest not using inhaled marijuana or ingested cannabidiol (CBD) oil for CACS given the lack of major evidence supporting benefit for this indication.</p><p>For the purpose of this review, "marijuana," "medical marijuana," and "cannabis" refer to naturally grown plant materials that are not regulated by the FDA and are procured by patients from legal marijuana dispensaries or street suppliers. The primary psychoactive ingredient is tetrahydrocannabinol (THC).</p><p>The term "cannabinoids" refers to several different entities:</p><p class="bulletIndent1"><span class="glyph">●</span>CBD is a naturally occurring molecule without psychoactive properties that is found in the cannabis plant. It can be procured by patients from legal marijuana dispensaries or street suppliers (often as CBD oil), and a purified form is available by prescription (Epidiolex) in the United States and approved for treatment of refractory epilepsy. (See  <a class="medical medical_review" href="/z/d/html/108722.html" rel="external">"Dravet syndrome: Management and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/138854.html" rel="external">"Lennox-Gastaut syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are three marketed drug products that contain synthetic THC. The only United States-approved cannabinoid (<a class="drug drug_general" data-topicid="9394" href="/z/d/drug information/9394.html" rel="external">dronabinol</a> [delta 9-THC]) is approved only for chemotherapy-induced nausea and vomiting. A second oral drug, <a class="drug drug_general" data-topicid="9995" href="/z/d/drug information/9995.html" rel="external">nabilone</a>, is approved in Canada and the UK, but was discontinued in the United States in 2019. Outside the United States, <a class="drug drug_general" data-topicid="9457" href="/z/d/drug information/9457.html" rel="external">nabiximols</a>, an oromucosal spray containing dronabinol plus CBD and smaller concentrations of other compounds (Sativex), is available and approved to relieve the spasticity associated with multiple sclerosis.</p><p></p><p>Anecdotal reports and small studies suggest that marijuana and THC supplementation stimulate appetite [<a href="#rid95">95-97</a>], prompting interest in the use of cannabinoids in patients with CACS.</p><p>A single phase II randomized double-blind placebo-controlled trial of CBD oil for relief of symptoms in advanced cancer concluded that CBD oil did not add value to the reduction in symptom distress (including loss of appetite) provided by specialist palliative care [<a href="#rid98">98</a>].</p><p>Unfortunately, synthetic cannabinoids have not been demonstrated to have activity against CACS in patients with advanced cancer [<a href="#rid99">99,100</a>], despite their activity in patients with advanced HIV disease (see  <a class="medical medical_review" href="/z/d/html/83234.html" rel="external">"Assessment and management of anorexia and cachexia in palliative care", section on 'Cannabis and cannabinoids'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>In a cooperative group trial, 469 evaluable patients with anorexia and/or weight loss were randomly assigned to <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a>, <a class="drug drug_general" data-topicid="9394" href="/z/d/drug information/9394.html" rel="external">dronabinol</a>, or both agents [<a href="#rid99">99</a>]. Significantly more patients had appetite improvement with megestrol acetate (73 versus 47 percent, compared with dronabinol) and nonfluid weight gain of ≥10 percent over baseline (13 versus 5 percent). Combined therapy with both megestrol acetate and dronabinol had no benefit beyond that obtained with megestrol acetate alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, benefit could not be shown in a European trial, in which 243 adults with advanced cancer and CACS were randomly assigned to <a class="drug drug_general" data-topicid="9394" href="/z/d/drug information/9394.html" rel="external">dronabinol</a> or a placebo [<a href="#rid100">100</a>]. No differences were observed between the groups in terms of appetite, quality of life, or cannabinoid-related toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Likewise, benefit could not be shown for <a class="drug drug_general" data-topicid="9995" href="/z/d/drug information/9995.html" rel="external">nabilone</a> (0.5 mg daily for two weeks, then 1 mg daily) in a small double-blind randomized trial of 47 patients with lung cancer [<a href="#rid101">101</a>]. Only 33 were assessable for outcome at eight weeks (the remainder were hospitalized, died, or were lost to follow-up). Although patients receiving nabilone had higher daily caloric intake at eight weeks (1181 versus 965 kcal per day), the difference was not statistically significant, there were no differences in appetite between the groups, and the higher caloric intake did not translate into any weight gain. Although there were reported improvements over baseline in some areas of health-related quality of life at eight weeks in those who received nabilone, there were imbalances between the two groups in baseline measures of several aspects of quality of life, and no significant differences in any aspect of quality of life emerged when the two groups were compared. Treatment-related side effects were not reported.</p><p></p><p>There are no high-quality published data on the efficacy of inhaled marijuana for patients with CACS.</p><p class="headingAnchor" id="H15"><span class="h3">TNF inhibitors</span><span class="headingEndMark"> — </span>As noted above, CACS is characterized by anorexia and a loss of body weight associated with reduced muscle mass and adipose tissue and increases in both muscle protein breakdown and lipolysis. These changes appear to be due in part to an inflammatory response with the elaboration of cytokines including TNF-alpha. (See  <a class="medical medical_review" href="/z/d/html/2817.html" rel="external">"Pathogenesis, clinical features, and assessment of cancer cachexia", section on 'Cytokines, inflammation, and the hypermetabolic state'</a>.)</p><p>Therapeutic strategies targeting TNF that have been explored for treatment of CACS include <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a>, a methylxanthine derivative that can inhibit TNF-alpha production by monocytes and T lymphocytes in vitro and reduce plasma concentrations and mRNA expression of this cytokine in patients with cancer [<a href="#rid102">102,103</a>], and <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a> and <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, both monoclonal antibodies that block TNF-alpha. Despite the compelling rationale underlying their use, small, placebo-controlled trials that have tested these three agents individually have failed to demonstrate benefit, reporting no positive effect on appetite or body weight [<a href="#rid104">104-106</a>].</p><p class="headingAnchor" id="H17"><span class="h3">Hydrazine sulfate</span><span class="headingEndMark"> — </span>We recommend against the use of hydrazine sulfate for managing cancer-associated cachexia. Hydrazine sulfate, an inhibitor of phosphoenolpyruvate kinase, an enzyme involved in gluconeogenesis, was widely touted for the treatment of CACS in the distant past. However, three placebo-controlled clinical trials failed to demonstrate any benefit in patients with advanced cancer [<a href="#rid107">107-109</a>]. Furthermore, central and peripheral neurotoxicity has been described with hydrazine, which is similar to that observed with the hydrazine-derived drug, <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a>. A fatal case of hepatorenal failure has also been described [<a href="#rid110">110</a>].</p><p class="headingAnchor" id="H19"><span class="h3">Insulin</span><span class="headingEndMark"> — </span>Treatment with low doses of insulin has been assessed in patients with advanced cancer in an effort to limit the progression of weight loss and improve physical functioning. In a trial in patients with advanced cancer, 138 patients were randomly assigned to intensive supportive care with or without insulin (0.11 units/kg/day) [<a href="#rid111">111</a>]. There was a suggestion of improvement based upon multiple metabolic parameters and overall survival, and there was no evidence to suggest that the insulin stimulated tumor growth.</p><p>Additional clinical trials would be required to further assess potential benefits and toxicity of insulin in this setting.</p><p class="headingAnchor" id="H21"><span class="h3">Melatonin</span><span class="headingEndMark"> — </span>Melatonin has been recommended to correct disturbances in the circadian rhythm; it also down-regulates production of TNF [<a href="#rid49">49</a>]. One study compared supportive care with the administration of melatonin (20 mg per night for three months) [<a href="#rid112">112</a>]. Although there was no difference in food intake, weight loss was significantly less in the melatonin-treated group. In a subsequent study, 70 consecutive patients with advanced NSCLC were randomized to receive chemotherapy with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> either alone or with melatonin (20 mg/day) [<a href="#rid113">113</a>]. The degree of cachexia and frequency of myelosuppression and neuropathy were significantly lower in those treated with melatonin, and the one-year survival of this group was increased (15 of 34 versus 7 of 36).</p><p>Unfortunately, benefit could not be confirmed in a subsequent double-blind trial in which 100 patients with advanced lung or gastrointestinal cancer, a history of weight loss ≥5 percent, and appetite scores ≥4 on a scale of 1 to 10 (with 10 being the worst appetite) were randomly assigned to melatonin 20 mg daily for 28 days or placebo [<a href="#rid114">114</a>]. The trial was closed after enrolling only 48 patients when a preplanned interim analysis disclosed no significant differences between the groups in appetite, weight, FAACT (Functional Assessment of Anorexia/Cachexia Therapy) scores, quality of life, toxicity, or survival.</p><p class="headingAnchor" id="H2980949310"><span class="h1">EXERCISE</span><span class="headingEndMark"> — </span>Outside of the context of a clinical trial, no recommendation can be made for other interventions such as exercise in patients with CACS.</p><p>The benefits of exercise to improve CACS are uncertain. A 2021 Cochrane review [<a href="#rid115">115</a>] identified four new studies [<a href="#rid84">84,116-118</a>] that had not been included in an earlier review [<a href="#rid119">119</a>]. These studies compared exercise against reasonable comparator arms and found no clear improvements in outcomes with exercise. The authors concluded that there is uncertainty of the effectiveness, acceptability, and safety of exercise for adults with cancer cachexia but assessed the certainty of the body of evidence as limited because of study limitations.</p><p>Several adequately powered randomized studies are underway to test exercise as a component of a multimodal cachexia intervention [<a href="#rid120">120,121</a>], and clearly high-quality research is needed and called for based on the conclusions of the meta-analysis cited directly above.</p><p class="headingAnchor" id="H15097070"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16248.html" rel="external">"Patient education: Managing loss of appetite and weight loss with cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The cancer-related anorexia/cachexia syndrome (CACS) is characterized by anorexia and a loss of body weight associated with reduced muscle mass and adipose tissue. While anorexia/cachexia is frequently seen in advanced cancer, it may also be a prominent feature of other end-stage, life-threatening illnesses. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/z/d/html/83234.html" rel="external">"Assessment and management of anorexia and cachexia in palliative care"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Our approach to management of CACS is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Communication regarding cachexia management and issues around feeding, particularly in the setting of advanced cancer or end-of-life care, should involve caregivers as well as patients. (See <a class="local">'Psychosocial impact and counseling'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Optimizing management of major contributors to anorexia, such as chronic nausea, constipation, taste alterations, dyspnea, and depression (nutrition impact symptoms), may improve appetite. (See <a class="local">'Treating nutrition impact symptoms'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Referral of patients with CACS to a registered dietician can provide practical and safe advice for feeding; education regarding high-protein, high-calorie, nutrient-dense food; and advice against fad diets and other unproven or extreme diets. However, referral is not mandatory for all patients. (See <a class="local">'Dietary counseling'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients with advanced cancer and CACS, we suggest not routinely using enteral tube feeding or <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> to manage cachexia (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). A short-term trial of parenteral nutrition may be offered to a very select group of patients (eg, reasonably fit patients with a reversible bowel obstruction, short-bowel syndrome, or other issues contributing to malabsorption). (See <a class="local">'Parenteral or nonvolitional enteral nutrition'</a> above and  <a class="medical medical_review" href="/z/d/html/2830.html" rel="external">"The role of parenteral and enteral/oral nutritional support in patients with cancer", section on 'Indications and benefits of nutritional support in cancer patients'</a> and  <a class="medical medical_review" href="/z/d/html/83234.html" rel="external">"Assessment and management of anorexia and cachexia in palliative care"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with cancer-associated anorexia/cachexia, we suggest <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> rather than other agents (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). We use a relatively low dose of 2.5 to 5 mg/day. Randomized trials demonstrate improvements in appetite and weight and decreased nausea/vomiting in patients with advanced cancer. Other, less favored, options include a trial with drugs such as <a class="drug drug_general" data-topicid="9603" href="/z/d/drug information/9603.html" rel="external">megestrol acetate</a> and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>.</p><p></p><p class="bulletIndent2">We do not use hydrazine sulfate, synthetic cannabinoids, inhaled cannabis, inhibitors of tumor necrosis factor, insulin, or melatonin for management of cancer-associated anorexia/cachexia.</p><p></p><p class="bulletIndent2">The evidence is inconclusive for androgens and selective androgen receptor modulators; anamorelin; <a class="drug drug_general" data-topicid="9311" href="/z/d/drug information/9311.html" rel="external">cyproheptadine</a>; long-chain omega-3 fatty acids; vitamins, minerals, and other dietary supplements; nonsteroidal anti-inflammatory drugs; <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>; <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">mirtazapine</a>; and combination approaches, and none of these approaches can be recommended. (See <a class="local">'Insufficient evidence to recommend for or against'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The benefits and safety of exercise as a treatment for CACS are uncertain. (See <a class="local">'Exercise'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hashida H, Takabayashi A, Tokuhara T, et al. Integrin alpha3 expression as a prognostic factor in colon cancer: association with MRP-1/CD9 and KAI1/CD82. Int J Cancer 2002; 97:518.</a></li><li><a class="nounderline abstract_t">Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69:491.</a></li><li><a class="nounderline abstract_t">Roeland EJ, Bohlke K, Baracos VE, et al. Management of Cancer Cachexia: ASCO Guideline. J Clin Oncol 2020; 38:2438.</a></li><li><a class="nounderline abstract_t">Roeland EJ, Bohlke K, Baracos VE, et al. Cancer Cachexia: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2023; 41:4178.</a></li><li><a class="nounderline abstract_t">Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer 2010; 18:951.</a></li><li><a class="nounderline abstract_t">Sandhya L, Devi Sreenivasan N, Goenka L, et al. Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer. J Clin Oncol 2023; 41:2617.</a></li><li><a class="nounderline abstract_t">Navari RM, Pywell CM, Le-Rademacher JG, et al. Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial. JAMA Oncol 2020; 6:895.</a></li><li><a class="nounderline abstract_t">Poole K, Froggatt K. Loss of weight and loss of appetite in advanced cancer: a problem for the patient, the carer, or the health professional? Palliat Med 2002; 16:499.</a></li><li><a class="nounderline abstract_t">Amano K, Baracos VE, Hopkinson JB. Integration of palliative, supportive, and nutritional care to alleviate eating-related distress among advanced cancer patients with cachexia and their family members. Crit Rev Oncol Hematol 2019; 143:117.</a></li><li><a class="nounderline abstract_t">Chai HZ, Krishna LK, Wong VH. Feeding: what it means to patients and caregivers and how these views influence Singaporean Chinese caregivers' decisions to continue feeding at the end of life. Am J Hosp Palliat Care 2014; 31:166.</a></li><li><a class="nounderline abstract_t">Orrevall Y. Nutritional support at the end of life. Nutrition 2015; 31:615.</a></li><li><a class="nounderline abstract_t">Farhangfar A, Makarewicz M, Ghosh S, et al. Nutrition impact symptoms in a population cohort of head and neck cancer patients: multivariate regression analysis of symptoms on oral intake, weight loss and survival. Oral Oncol 2014; 50:877.</a></li><li><a class="nounderline abstract_t">Del Fabbro E, Hui D, Dalal S, et al. Clinical outcomes and contributors to weight loss in a cancer cachexia clinic. J Palliat Med 2011; 14:1004.</a></li><li><a class="nounderline abstract_t">Baldwin C, Spiro A, Ahern R, Emery PW. Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2012; 104:371.</a></li><li><a class="nounderline abstract_t">de van der Schueren MAE, Laviano A, Blanchard H, et al. Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials. Ann Oncol 2018; 29:1141.</a></li><li><a class="nounderline abstract_t">Balstad TR, Solheim TS, Strasser F, et al. Dietary treatment of weight loss in patients with advanced cancer and cachexia: a systematic literature review. Crit Rev Oncol Hematol 2014; 91:210.</a></li><li><a class="nounderline abstract_t">Ovesen L, Allingstrup L, Hannibal J, et al. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol 1993; 11:2043.</a></li><li><a class="nounderline abstract_t">Zick SM, Snyder D, Abrams DI. Pros and Cons of Dietary Strategies Popular Among Cancer Patients. Oncology (Williston Park) 2018; 32:542.</a></li><li><a class="nounderline abstract_t">Luo Q, Asher GN. Use of Dietary Supplements at a Comprehensive Cancer Center. J Altern Complement Med 2018; 24:981.</a></li><li><a class="nounderline abstract_t">Loprinzi CL, Schaid DJ, Dose AM, et al. Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993; 11:152.</a></li><li><a class="nounderline abstract_t">Madeddu C, Macciò A, Panzone F, et al. Medroxyprogesterone acetate in the management of cancer cachexia. Expert Opin Pharmacother 2009; 10:1359.</a></li><li><a class="nounderline abstract_t">Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, et al. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2013; :CD004310.</a></li><li><a class="nounderline abstract_t">Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990; 82:1127.</a></li><li><a class="nounderline abstract_t">Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999; 17:3299.</a></li><li><a class="nounderline abstract_t">Yavuzsen T, Davis MP, Walsh D, et al. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol 2005; 23:8500.</a></li><li><a class="nounderline abstract_t">Cuvelier GD, Baker TJ, Peddie EF, et al. A randomized, double-blind, placebo-controlled clinical trial of megestrol acetate as an appetite stimulant in children with weight loss due to cancer and/or cancer therapy. Pediatr Blood Cancer 2014; 61:672.</a></li><li><a class="nounderline abstract_t">Maltoni M, Nanni O, Scarpi E, et al. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Ann Oncol 2001; 12:289.</a></li><li><a class="nounderline abstract_t">Pascual López A, Roqué i Figuls M, Urrútia Cuchi G, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 2004; 27:360.</a></li><li><a class="nounderline abstract_t">Advani SM, Advani PG, VonVille HM, Jafri SH. Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials. BMC Cancer 2018; 18:1174.</a></li><li><a class="nounderline abstract_t">Ruiz-García V, López-Briz E, Carbonell-Sanchis R, et al. Megestrol acetate for cachexia-anorexia syndrome. A systematic review. J Cachexia Sarcopenia Muscle 2018; 9:444.</a></li><li><a class="nounderline abstract_t">Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993; 11:762.</a></li><li><a class="nounderline abstract_t">Vadell C, Seguí MA, Giménez-Arnau JM, et al. Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. Am J Clin Oncol 1998; 21:347.</a></li><li><a class="nounderline abstract_t">Bruera E, Ernst S, Hagen N, et al. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev Control 1998; 2:74.</a></li><li><a class="nounderline abstract_t">Pardo J, Mena AM, Motnsech L, et al. Megestrol acetate for anorexia in lung cancer patients undergoing radiation therapy. A randomized trial comparing the efficacy of two different doses in 130 patients (abstract). Proc Am Soc Clin Oncol 2003; 22:765a.</a></li><li><a class="nounderline abstract_t">Rowland KM Jr, Loprinzi CL, Shaw EG, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 1996; 14:135.</a></li><li><a class="nounderline abstract_t">Leinung MC, Liporace R, Miller CH. Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med 1995; 122:843.</a></li><li><a class="nounderline abstract_t">Mann M, Koller E, Murgo A, et al. Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 1997; 157:1651.</a></li><li><a class="nounderline abstract_t">Dev R, Del Fabbro E, Bruera E. Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer. Cancer 2007; 110:1173.</a></li><li><a class="nounderline abstract_t">Simons JP, Aaronson NK, Vansteenkiste JF, et al. Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. J Clin Oncol 1996; 14:1077.</a></li><li><a class="nounderline abstract_t">Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974; 33:1607.</a></li><li><a class="nounderline abstract_t">Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985; 69:751.</a></li><li><a class="nounderline abstract_t">Popiela T, Lucchi R, Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 1989; 25:1823.</a></li><li><a class="nounderline abstract_t">Chlebowski RT, Herrold J, Ali I, et al. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer 1986; 58:183.</a></li><li><a class="nounderline abstract_t">Dobs AS, Boccia RV, Croot CC, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol 2013; 14:335.</a></li><li><a class="nounderline abstract_t">Crawford J, Prado CM, Johnston MA, et al. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Curr Oncol Rep 2016; 18:37.</a></li><li><a class="nounderline abstract_t">Wright TJ, Dillon EL, Durham WJ, et al. A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women. J Cachexia Sarcopenia Muscle 2018; 9:482.</a></li><li><a class="nounderline abstract_t">Bartlett DL, Stein TP, Torosian MH. Effect of growth hormone and protein intake on tumor growth and host cachexia. Surgery 1995; 117:260.</a></li><li><a class="nounderline abstract_t">Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341:785.</a></li><li><a class="nounderline abstract_t">Kotler DP. Cachexia. Ann Intern Med 2000; 133:622.</a></li><li><a class="nounderline abstract_t">Strasser F, Lutz TA, Maeder MT, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer 2008; 98:300.</a></li><li><a class="nounderline abstract_t">Lundholm K, Gunnebo L, Körner U, et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer 2010; 116:2044.</a></li><li><a class="nounderline abstract_t">Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89:2832.</a></li><li><a class="nounderline abstract_t">Khatib MN, Shankar AH, Kirubakaran R, et al. Ghrelin for the management of cachexia associated with cancer. Cochrane Database Syst Rev 2018; 2:CD012229.</a></li><li><a class="nounderline abstract_t">Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 2013; 21:129.</a></li><li><a class="nounderline abstract_t">Garcia JM, Boccia RV, Graham CD, et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol 2015; 16:108.</a></li><li><a class="nounderline abstract_t">Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 2016; 17:519.</a></li><li><a class="nounderline abstract_t">Takayama K, Katakami N, Yokoyama T, et al. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Support Care Cancer 2016; 24:3495.</a></li><li><a class="nounderline abstract_t">Katakami N, Uchino J, Yokoyama T, et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 2018; 124:606.</a></li><li><a class="nounderline abstract_t">Nishie K, Yamamoto S, Nagata C, et al. Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis. Lung Cancer 2017; 112:25.</a></li><li><a class="nounderline abstract_t">Hamauchi S, Furuse J, Takano T, et al. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer 2019; 125:4294.</a></li><li><a class="nounderline abstract_t">Naito T, Uchino J, Kojima T, et al. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index. Cancer 2022; 128:2025.</a></li><li><a class="nounderline abstract_t">Currow D, Temel JS, Abernethy A, et al. ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann Oncol 2017; 28:1949.</a></li><li><a class="nounderline abstract_t">Bai Y, Hu Y, Zhao Y, et al. Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis. Support Care Cancer 2017; 25:1651.</a></li><li><a class="nounderline abstract_t">Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990; 65:2657.</a></li><li><a class="nounderline abstract_t">Moertel CG, Kvols LK, Rubin J. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 1991; 67:33.</a></li><li><a class="nounderline abstract_t">Price SA, Tisdale MJ. Mechanism of inhibition of a tumor lipid-mobilizing factor by eicosapentaenoic acid. Cancer Res 1998; 58:4827.</a></li><li><a class="nounderline abstract_t">Wigmore SJ, Fearon KC, Maingay JP, Ross JA. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clin Sci (Lond) 1997; 92:215.</a></li><li><a class="nounderline abstract_t">Fearon KC, Von Meyenfeldt MF, Moses AG, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003; 52:1479.</a></li><li><a class="nounderline abstract_t">Bruera E, Strasser F, Palmer JL, et al. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol 2003; 21:129.</a></li><li><a class="nounderline abstract_t">Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004; 22:2469.</a></li><li><a class="nounderline abstract_t">Fearon KC, Barber MD, Moses AG, et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006; 24:3401.</a></li><li><a class="nounderline abstract_t">Murphy RA, Mourtzakis M, Chu QS, et al. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 2011; 117:1775.</a></li><li><a class="nounderline abstract_t">Ryan AM, Reynolds JV, Healy L, et al. Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial. Ann Surg 2009; 249:355.</a></li><li><a class="nounderline abstract_t">van der Meij BS, Langius JA, Smit EF, et al. Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment. J Nutr 2010; 140:1774.</a></li><li><a class="nounderline abstract_t">Weed HG, Ferguson ML, Gaff RL, et al. Lean body mass gain in patients with head and neck squamous cell cancer treated perioperatively with a protein- and energy-dense nutritional supplement containing eicosapentaenoic acid. Head Neck 2011; 33:1027.</a></li><li><a class="nounderline abstract_t">Murphy RA, Yeung E, Mazurak VC, Mourtzakis M. Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia. Br J Cancer 2011; 105:1469.</a></li><li><a class="nounderline abstract_t">Dewey A, Baughan C, Dean T, et al. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev 2007; :CD004597.</a></li><li><a class="nounderline abstract_t">Ries A, Trottenberg P, Elsner F, et al. A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project. Palliat Med 2012; 26:294.</a></li><li><a class="nounderline abstract_t">Ma YJ, Yu J, Xiao J, Cao BW. The consumption of omega-3 polyunsaturated fatty acids improves clinical outcomes and prognosis in pancreatic cancer patients: a systematic evaluation. Nutr Cancer 2015; 67:112.</a></li><li><a class="nounderline abstract_t">Pisters PW, Pearlstone DB. Protein and amino acid metabolism in cancer cachexia: investigative techniques and therapeutic interventions. Crit Rev Clin Lab Sci 1993; 30:223.</a></li><li><a class="nounderline abstract_t">Kraft M, Kraft K, Gärtner S, et al. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial. Nutr J 2012; 11:52.</a></li><li><a class="nounderline abstract_t">Jatoi A, Steen PD, Atherton PJ, et al. A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial. Ann Oncol 2017; 28:1957.</a></li><li><a class="nounderline abstract_t">Mochamat, Cuhls H, Marinova M, et al. A systematic review on the role of vitamins, minerals, proteins, and other supplements for the treatment of cachexia in cancer: a European Palliative Care Research Centre cachexia project. J Cachexia Sarcopenia Muscle 2017; 8:25.</a></li><li><a class="nounderline abstract_t">Solheim TS, Laird BJA, Balstad TR, et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle 2017; 8:778.</a></li><li><a class="nounderline abstract_t">Kouchaki B, Janbabai G, Alipour A, et al. Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers. Support Care Cancer 2018; 26:2479.</a></li><li><a class="nounderline abstract_t">McMillan DC, Wigmore SJ, Fearon KC, et al. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999; 79:495.</a></li><li><a class="nounderline abstract_t">Reid J, Mills M, Cantwell M, et al. Thalidomide for managing cancer cachexia. Cochrane Database Syst Rev 2012; :CD008664.</a></li><li><a class="nounderline abstract_t">Gordon JN, Trebble TM, Ellis RD, et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005; 54:540.</a></li><li><a class="nounderline abstract_t">Yennurajalingam S, Willey JS, Palmer JL, et al. The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study. J Palliat Med 2012; 15:1059.</a></li><li><a class="nounderline abstract_t">Riechelmann RP, Burman D, Tannock IF, et al. Phase II trial of mirtazapine for cancer-related cachexia and anorexia. Am J Hosp Palliat Care 2010; 27:106.</a></li><li><a class="nounderline abstract_t">Hunter CN, Abdel-Aal HH, Elsherief WA, et al. Mirtazapine in Cancer-Associated Anorexia and Cachexia: A Double-Blind Placebo-Controlled Randomized Trial. J Pain Symptom Manage 2021; 62:1207.</a></li><li><a class="nounderline abstract_t">Madeddu C, Dessì M, Panzone F, et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clin Nutr 2012; 31:176.</a></li><li><a class="nounderline abstract_t">Macciò A, Madeddu C, Gramignano G, et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 2012; 124:417.</a></li><li><a class="nounderline abstract_t">Mantovani G, Macciò A, Madeddu C, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010; 15:200.</a></li><li><a class="nounderline abstract_t">Abel EL. Effects of marihuana on the solution of anagrams, memory and appetite. Nature 1971; 231:260.</a></li><li><a class="nounderline abstract_t">Anderson SP, Zylla DM, McGriff DM, Arneson TJ. Impact of Medical Cannabis on Patient-Reported Symptoms for Patients With Cancer Enrolled in Minnesota's Medical Cannabis Program. J Oncol Pract 2019; 15:e338.</a></li><li><a class="nounderline abstract_t">Abrams DI, Guzman M. Cannabis in cancer care. Clin Pharmacol Ther 2015; 97:575.</a></li><li><a class="nounderline abstract_t">Hardy J, Greer R, Huggett G, et al. Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD). J Clin Oncol 2023; 41:1444.</a></li><li><a class="nounderline abstract_t">Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20:567.</a></li><li><a class="nounderline abstract_t">Cannabis-In-Cachexia-Study-Group, Strasser F, Luftner D, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006; 24:3394.</a></li><li><a class="nounderline abstract_t">Turcott JG, Del Rocío Guillen Núñez M, Flores-Estrada D, et al. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer 2018; 26:3029.</a></li><li><a class="nounderline abstract_t">Lissoni P, Ardizzoia A, Perego MS, et al. Inhibition of tumor necrosis factor-alpha secretion by pentoxifylline in advanced cancer patients with abnormally high blood levels of tumor necrosis factor-alpha. J Biol Regul Homeost Agents 1993; 7:73.</a></li><li><a class="nounderline abstract_t">Dezube BJ, Sherman ML, Fridovich-Keil JL, et al. Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. Cancer Immunol Immunother 1993; 36:57.</a></li><li><a class="nounderline abstract_t">Goldberg RM, Loprinzi CL, Mailliard JA, et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 1995; 13:2856.</a></li><li><a class="nounderline abstract_t">Jatoi A, Dakhil SR, Nguyen PL, et al. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer 2007; 110:1396.</a></li><li><a class="nounderline abstract_t">Jatoi A, Ritter HL, Dueck A, et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer 2010; 68:234.</a></li><li><a class="nounderline abstract_t">Loprinzi CL, Goldberg RM, Su JQ, et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 1994; 12:1126.</a></li><li><a class="nounderline abstract_t">Loprinzi CL, Kuross SA, O'Fallon JR, et al. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 1994; 12:1121.</a></li><li><a class="nounderline abstract_t">Kosty MP, Fleishman SB, Herndon JE 2nd, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1994; 12:1113.</a></li><li><a class="nounderline abstract_t">Hainer MI, Tsai N, Komura ST, Chiu CL. Fatal hepatorenal failure associated with hydrazine sulfate. Ann Intern Med 2000; 133:877.</a></li><li><a class="nounderline abstract_t">Lundholm K, Körner U, Gunnebo L, et al. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res 2007; 13:2699.</a></li><li><a class="nounderline abstract_t">Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 1996; 32A:1340.</a></li><li><a class="nounderline abstract_t">Lissoni P, Paolorossi F, Ardizzoia A, et al. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res 1997; 23:15.</a></li><li><a class="nounderline abstract_t">Del Fabbro E, Dev R, Hui D, et al. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol 2013; 31:1271.</a></li><li><a class="nounderline abstract_t">Grande AJ, Silva V, Sawaris Neto L, et al. Exercise for cancer cachexia in adults. Cochrane Database Syst Rev 2021; 3:CD010804.</a></li><li><a class="nounderline abstract_t">Grote M, Maihöfer C, Weigl M, et al. Progressive resistance training in cachectic head and neck cancer patients undergoing radiotherapy: a randomized controlled pilot feasibility trial. Radiat Oncol 2018; 13:215.</a></li><li><a class="nounderline abstract_t">Capozzi LC, McNeely ML, Lau HY, et al. Patient-reported outcomes, body composition, and nutrition status in patients with head and neck cancer: Results from an exploratory randomized controlled exercise trial. Cancer 2016; 122:1185.</a></li><li><a class="nounderline abstract_t">Forget F, Frusch N, Trokay L, et al. A randomized trial comparing best supportive care (BSC) versus multimodality approach (MA) to fight against cachexia in patients with cancer treated with chemotherapy. J Clin Oncol 2014; 32S:ASCO #e20655.</a></li><li><a class="nounderline abstract_t">Grande AJ, Silva V, Riera R, et al. Exercise for cancer cachexia in adults. Cochrane Database Syst Rev 2014; :CD010804.</a></li><li class="breakAll">https://clinicaltrials.gov/ct2/show/NCT04065815?term=exercise&amp;cond=cancer+cachexia&amp;draw=2&amp;rank=2 (Accessed on July 07, 2020).</li><li class="breakAll">https://clinicaltrials.gov/ct2/show/NCT02330926?term=exercise&amp;cond=cancer+cachexia&amp;draw=3&amp;rank=17 (Accessed on July 07, 2020).</li></ol></div><div id="topicVersionRevision">Topic 2816 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11802216" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Integrin alpha3 expression as a prognostic factor in colon cancer: association with MRP-1/CD9 and KAI1/CD82.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7424938" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32432946" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Management of Cancer Cachexia: ASCO Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37467399" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cancer Cachexia: ASCO Guideline Rapid Recommendation Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19756773" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36977285" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32379269" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12465697" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Loss of weight and loss of appetite in advanced cancer: a problem for the patient, the carer, or the health professional?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31563078" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Integration of palliative, supportive, and nutritional care to alleviate eating-related distress among advanced cancer patients with cachexia and their family members.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23503566" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Feeding: what it means to patients and caregivers and how these views influence Singaporean Chinese caregivers' decisions to continue feeding at the end of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25770331" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Nutritional support at the end of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25017804" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nutrition impact symptoms in a population cohort of head and neck cancer patients: multivariate regression analysis of symptoms on oral intake, weight loss and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21793729" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical outcomes and contributors to weight loss in a cancer cachexia clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22345712" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29788170" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24703549" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Dietary treatment of weight loss in patients with advanced cancer and cachexia: a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8410128" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30474102" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pros and Cons of Dietary Strategies Popular Among Cancer Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30247972" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Use of Dietary Supplements at a Comprehensive Cancer Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8418227" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Body-composition changes in patients who gain weight while receiving megestrol acetate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19445562" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Medroxyprogesterone acetate in the management of cancer cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23543530" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Megestrol acetate for treatment of anorexia-cachexia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2193166" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10506633" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16293879" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Systematic review of the treatment of cancer-associated anorexia and weight loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24167059" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : A randomized, double-blind, placebo-controlled clinical trial of megestrol acetate as an appetite stimulant in children with weight loss due to cancer and/or cancer therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11332139" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15050664" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30482179" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29542279" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Megestrol acetate for cachexia-anorexia syndrome. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8478668" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9708631" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9765767" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Megestrol acetate for anorexia in lung cancer patients undergoing radiation therapy. A randomized trial comparing the efficacy of two different doses in 130 patients (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558188" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7741369" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Induction of adrenal suppression by megestrol acetate in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9250225" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17647248" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Association between megestrol acetate treatment and symptomatic adrenal insufficiency with hypogonadism in male patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8648360" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4135151" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Corticosteroid therapy of preterminal gastrointestinal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2410117" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2483687" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3518910" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23499390" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27138015" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29654645" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7878530" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effect of growth hormone and protein intake on tumor growth and host cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10477776" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Increased mortality associated with growth hormone treatment in critically ill adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11033592" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18182992" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20186829" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15181065" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29489032" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Ghrelin for the management of cachexia associated with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22699302" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25524795" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26906526" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27005463" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29205286" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29191597" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31415709" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35195274" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28472437" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28074289" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2187585" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1985720" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9809986" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Mechanism of inhibition of a tumor lipid-mobilizing factor by eicosapentaenoic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9059324" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12970142" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12506181" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15197210" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16849754" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21360698" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19247018" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20739445" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20967868" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Lean body mass gain in patients with head and neck squamous cell cancer treated perioperatively with a protein- and energy-dense nutritional supplement containing eicosapentaenoic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21970879" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17253515" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21865295" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25425246" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The consumption of omega-3 polyunsaturated fatty acids improves clinical outcomes and prognosis in pancreatic cancer patients: a systematic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8260072" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Protein and amino acid metabolism in cancer cachexia: investigative techniques and therapeutic interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22824168" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28475678" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A double-blind, placebo-controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27897391" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A systematic review on the role of vitamins, minerals, proteins, and other supplements for the treatment of cachexia in cancer: a European Palliative Care Research Centre cachexia project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28614627" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29442239" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Randomized double-blind clinical trial of combined treatment with megestrol acetate plus celecoxib versus megestrol acetate alone in cachexia-anorexia syndrome induced by GI cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10027319" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22513961" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Thalidomide for managing cancer cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15753541" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22880820" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19776373" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Phase II trial of mirtazapine for cancer-related cachexia and anorexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34051293" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Mirtazapine in Cancer-Associated Anorexia and Cachexia: A Double-Blind Placebo-Controlled Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22047681" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib±megestrol acetate for patients with cancer-related anorexia/cachexia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22198049" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20156909" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4930692" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Effects of marihuana on the solution of anagrams, memory and appetite.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30860938" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Impact of Medical Cannabis on Patient-Reported Symptoms for Patients With Cancer Enrolled in Minnesota's Medical Cannabis Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25777363" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Cannabis in cancer care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36409969" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11786587" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16849753" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29550881" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8266818" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Inhibition of tumor necrosis factor-alpha secretion by pentoxifylline in advanced cancer patients with abnormally high blood levels of tumor necrosis factor-alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7678547" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7595749" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17674351" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19665818" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8201374" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8201373" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8201372" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11103057" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Fatal hepatorenal failure associated with hydrazine sulfate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17473202" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8869096" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Is there a role for melatonin in the treatment of neoplastic cachexia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9379341" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23439759" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33735441" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Exercise for cancer cachexia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30400971" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Progressive resistance training in cachectic head and neck cancer patients undergoing radiotherapy: a randomized controlled pilot feasibility trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26828426" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Patient-reported outcomes, body composition, and nutrition status in patients with head and neck cancer: Results from an exploratory randomized controlled exercise trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : A randomized trial comparing best supportive care (BSC) versus multimodality approach (MA) to fight against cachexia in patients with cancer treated with chemotherapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25424884" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Exercise for cancer cachexia in adults.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
